| (Values in U.S. Thousands) | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 | Mar, 2018 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -71,890 | -32,430 | -72,630 | -129,070 | -221,570 |
| Net Income Growth | -121.68% | +55.35% | +43.73% | +41.75% | -22.45% |
Sio Gene Therapies Inc (SIOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sio Gene Therapies Inc. is a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. Its product candidate includes AXO-AAV-GM1 and AXO-AAV-GM. Sio Gene Therapies Inc., formerly known as Axovant Gene Therapies Ltd., is based in New York.
Fiscal Year End Date: 03/31